Item 8.01 Other Events.
On January 3, 2023, Aurinia announced it has entered into a settlement agreement
with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd.,
and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both
Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing
Inter Partes Review (IPR) directed at Aurinia's U.S. Patent No. 10,286,036, as
well as settlement of the ongoing patent infringement litigation in the United
States (U.S.) related to Sun's CEQUA® product. Under the settlement agreement,
which is contingent upon the U.S. Patent Trial and Appeal Board approving the
joint motion to terminate the IPR, both parties agreed to dismiss their claims
and counterclaims against each other and cease bringing any future further
action against the other.
The information in this Current Report on Form 8-K is being furnished and shall
not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liabilities of that
section, nor shall they be deemed incorporated by reference into any of our
filings under the Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, whether made before or after the date hereof,
regardless of any general incorporation language in such filing. The furnishing
of this information hereby shall not be deemed an admission as to the
materiality of any such information.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses